• views: 21
• date: 25 October 2026
• posted by: BeMyLove

This third volume in the series focuses on such germane issues as the weight of evidence approach, applying the 3Rs (replacement, reduction, and refinement), personalized drug therapies, and oncology therapeutics, among others. Volumes in this series are aimed at toxicologists, toxicologic pathologists, regulators, and study directors dealing with issues in study design, evaluation of findings, and presentation of data. In addition, the series will serve as an aid to academicians and graduate students studying nonclinical drug development. Key Features: • Explores the critical issues and current topics important in nonclinical drug development • Deals with day-to-day issues in study design, evaluation of findings, and presentation of data • Aids academicians and graduate students pursuing research related to nonclinical drug development • Delves into both the art and science of nonclinical drug development and its impact on translational medicine and human safety



   
   
   

Forex Trading

Crypto Trading. 20 USD Bonus after KYC

We need your support!
Make a donation to help us stay online
        
Bitcoin (BTC)
bc1q08g9d22cxkawsjlf8etuek2pc9n2a3hs4cdrld
	
Bitcoin Cash (BCH)
qqvwexzhvgauxq2apgc4j0ewvcak6hh6lsnzmvtkem

Ethereum (ETH)
0xb55513D2c91A6e3c497621644ec99e206CDaf239

Litecoin (LTC)
ltc1qt6g2trfv9tjs4qj68sqc4uf0ukvc9jpnsyt59u

USDT (ERC20)
0xb55513D2c91A6e3c497621644ec99e206CDaf239

USDT (TRC20)
TYdPNrz7v1P9riWBWZ317oBgJueheGjATm

0 1 2 3 4 5

| Print version |

	Information
		Users of GUESTS are not allowed to comment this publication.